NEW YORK (GenomeWeb) – Illumina anticipates that pharmaceutical companies developing companion diagnostic tests will leverage its TruSight Tumor 170 panel, which will begin shipping to customers in the first quarter of 2017 for research use only.

The new panel leverages a hybrid capture technique that enables both DNA and RNA to be analyzed simultaneously, John Leite, Illumina's VP of oncology, told GenomeWeb.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.